Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Anemia Clinical Trial

Official title:

Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00771810
• Other study ID #: TXA127-2007-002
• Status: Completed
• Phase: Phase 2
• First received: October 9, 2008
• Last updated: October 10, 2017
• Start date: October 2008
• Est. completion date: December 2011

Study information

• Verified date: October 2017
• Source: Tarix Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study will investigate the safety and effectiveness of two different dose levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine and carboplatin or gemcitabine and cisplatin prescribed to women for the treatment of ovarian cancer. This experimental drug is called TXA127 and is being tested for effectiveness to see if it will help reduce some of the side effects of the chemotherapy, primarily low blood platelet levels that lead to excess bleeding. This study also intends to test the safety of TXA127 when given as an injection under the skin on a daily basis concurrently with up to 6 cycles of the prescribed chemotherapy.

Description:

This is a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study comparing safety and efficacy of two dose levels of TXA127 when administered during 6 cycles of combination gemcitabine and platinum-based chemotherapy. This study intends to investigate the effectiveness of TXA127 for the mitigation of severity and/or incidence of thrombocytopenia, as well as safety when administered as a self-injected, subcutaneous solution.

Females 18 years of age or older with a confirmed diagnosis of ovarian carcinoma who are scheduled to undergo combination chemotherapy with gemcitabine and carboplatin or gemcitabine and cisplatin will be considered for this study. Subjects may be chemotherapy naïve, newly diagnosed, or post a single course of chemotherapy followed by a progression- and treatment-free interval of at least 3 months, or post 2 or more previous courses of chemotherapy after a progression- and treatment-free interval of at least 6 months.

Subjects will be randomized in a 1:1:1 ratio to one of the following three blinded treatment groups: placebo, 100 ug/kg/day TXA127 and 300 ug/kg/day TXA127.

Treatment will be concurrent with up to six consecutive 21-day cycles of one of the following gemcitabine and platin regimens:

Regimen A

• Intravenous cisplatin therapy at a dose of 30-50 mg/m2 given on Day 1 of the cycle

• Intravenous gemcitabine at a dose of 800 mg/m2 given on Day 1 after cisplatin and on Day 8 of the cycle.

Regimen B

• Intravenous gemcitabine at a dose of 1000 mg/m2 given on Days 1 and 8 of the cycle

• Intravenous carboplatin AUC 4 given after gemcitabine on Day 1 of the cycle

TXA127 will be self-administered as a subcutaneous injection by the subject once daily on Days 2-6 and 9-15 during each cycle of chemotherapy. Blood specimens will be drawn for hematologic analysis on Days 1, 8 and 15 of each treatment cycle.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Females at least 18 years of age with ovarian carcinoma who are one of the following:

• Newly diagnosed with ovarian cancer and chemotherapy naïve, or

• Post a single previous course of chemotherapy, with a 3-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit, or

• Post two or more previous courses of chemotherapy with a 6-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit.

• Must be scheduled for a course of combination chemotherapy consisting of gemcitabine and cisplatin or gemcitabine and carboplatin to be administered in 21-day cycles

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

• Adequate bone marrow, renal, and hepatic functions as measured by standard chemistry and hematology blood tests

• Adequate blood coagulation parameters as measured by standard blood tests for coagulation

Exclusion Criteria:

• Any clinical or laboratory abnormality greater than Grade 2 toxicity (NCI criteria), with the exception of laboratory parameters specified in the inclusion criteria

• Significant unstable cardiovascular disease

• Uncontrolled high blood pressure

• Current use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II antagonists

• Evidence of metastatic disease to the bone

• Metastatic disease to the CNS requiring treatment or radiation therapy

• Uncontrolled infection(s)

• Radiation therapy or chemotherapy (except as specified in the inclusion criteria) within the previous 5 years

• Concurrent use of hematopoietic or erythropoietic agents

Related Conditions & MeSH terms

• Anemia
• Lymphopenia
• Neutropenia
• Thrombocytopenia

Intervention

Drug:
• TXA127
Once daily subcutaneous injection of 100 ug/kg
• TXA127
Once daily subcutaneous injection of 300 ug/kg
• Placebo
Once daily subcutaneous injection of placebo

Locations

Country	Name	City	State
United States	Schwartz Gynecologic Oncology, PLLC	Brightwaters	New York
United States	Rush University Medical Center	Chicago	Illinois
United States	USC - LAC Medical Center	Los Angeles	California
United States	University of Southern Alabama Mitchell Cancer Institute	Mobile	Alabama
United States	University of California - Irvine, Chao Family Comprehensive Cancer Center	Orange	California
United States	Associates in Women's Health	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Tarix Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (2)

Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004 Jan;53(1):15-24. Epub 2003 Oct 16. — View Citation

Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006 May;57(5):559-68. Epub 2005 Aug 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3	Mean percentage of cycles with platelet counts below 50,000/mm3	During a maximum of six 3-week chemotherapy cycles
Secondary	Subjects With Platelet Counts Below 50,000/mm3	Number of subjects who experienced a platelet count below 50,000/mm3	During a maximum of six 3-week chemotherapy cycles
Secondary	Treatment Cycles With Platelets Counts Below 25,000/mm3	Mean percentage of treatment cycles where platelets counts were below 25,000/mm3	During a maximum of six 3-week chemotherapy cycles
Secondary	Chemotherapy Dose Intensity and Dose Density	Mean percentage of cycles where projected (target) chemotherapy dose was maintained	During a maximum of six 3-week chemotherapy cycles
Secondary	Lymphopenia as Determined by Lymphocyte Count	Number of subjects with a treatment emergent adverse event of lymphopenia	During a maximum of six 3-week chemotherapy cycles
Secondary	Neutropenia	Number of subjects with a treatment emergent adverse event of neutropenia	During a maximum of six 3-week chemotherapy cycles
Secondary	Anemia	Number of subjects with a treatment emergent adverse event of anemia	During a maximum of six 3-week chemotherapy cycles
Secondary	Mucositis	Number of subjects with a treatment emergent adverse event of mucositis	During a maximum of six 3-week chemotherapy cycles
Secondary	Alopecia	Number of subjects with a treatment emergent adverse event of alopecia	During a maximum of six 3-week chemotherapy cycles
Secondary	Rescue Treatment for Hematopoiesis and Mucositis	Number of subjects with a treatment emergent adverse event of hematopoiesis and mucositis who received rescue treatment as determined by the administration of: Transfusions; Filgrastim or Pegfilgrastim; Erythropoietin; Palifermin	During a maximum of six 3-week chemotherapy cycles